Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele R Wilson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Managed Care Interface|December 2, 2006
The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgetsStephanie R Earnshaw, Michele R Wilson, Ashish V Joshi
Stroke|September 30, 2006
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhageStephanie R Earnshaw, Ashish V Joshi, Michele R Wilson, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 31, 2017
Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UKMichele R Wilson, Ismail Azzabi Zouraq, Helene Chevrou-Severac, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 9, 2017
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United KingdomMichele R Wilson, Annika Bergman, Helene Chevrou-Severac, et al.
Infectious Diseases and Therapy|July 12, 2021
Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from BelgiumMichele R Wilson, Cheryl L McDade, Johnna E Perdrizet, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 11, 2017
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelMichele R Wilson, Jeetvan G Patel, Amber Coleman, et al.
Infectious Diseases and Therapy|February 11, 2023
Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal DiseaseLiping Huang, Cheryl L McDade, Johnna E Perdrizet, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.
Journal of Medical Economics|July 18, 2025
Budget impact analysis of Haemate-<i>P</i> as long-term prophylaxis and on-demand therapy for von Willebrand disease in SpainMichele R Wilson, Pablo Mendez, Cheryl L McDade, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Managed Care Interface|December 2, 2006
The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgetsStephanie R Earnshaw, Michele R Wilson, Ashish V Joshi
Stroke|September 30, 2006
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhageStephanie R Earnshaw, Ashish V Joshi, Michele R Wilson, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 31, 2017
Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UKMichele R Wilson, Ismail Azzabi Zouraq, Helene Chevrou-Severac, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 9, 2017
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United KingdomMichele R Wilson, Annika Bergman, Helene Chevrou-Severac, et al.
Infectious Diseases and Therapy|July 12, 2021
Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from BelgiumMichele R Wilson, Cheryl L McDade, Johnna E Perdrizet, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 11, 2017
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelMichele R Wilson, Jeetvan G Patel, Amber Coleman, et al.
Infectious Diseases and Therapy|February 11, 2023
Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal DiseaseLiping Huang, Cheryl L McDade, Johnna E Perdrizet, et al.
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.
Journal of Medical Economics|July 18, 2025
Budget impact analysis of Haemate-<i>P</i> as long-term prophylaxis and on-demand therapy for von Willebrand disease in SpainMichele R Wilson, Pablo Mendez, Cheryl L McDade, et al.
Pageof 2